FDA au­tho­rizes bi­va­lent Covid boost­ers for chil­dren 6 months and up

Kids 6 months and old­er are now el­i­gi­ble to re­ceive Omi­cron-spe­cif­ic boost­ers for Covid-19, as US vac­ci­na­tion rates among chil­dren re­main low.

The FDA on Thurs­day ex­tend­ed the emer­gency use au­tho­riza­tions for both Mod­er­na and Pfiz­er’s up­dat­ed bi­va­lent vac­cines, which in­clude mR­NA com­po­nents of the orig­i­nal coro­n­avirus strain and the BA.4 and BA.5 lin­eages.

The Omi­cron BQ.1 and BQ.1.1 strains are cur­rent­ly dom­i­nant in the US, ac­count­ing for more than 60% of all cas­es, ac­cord­ing to the CDC’s track­er.

The US has seen slow up­take of the new boost­er shots, and on­ly 12.7% of those 5 years and old­er have re­ceived the up­dat­ed dose, the CDC re­ports.

Vac­cine rates among very young chil­dren are es­pe­cial­ly low. De­spite be­ing el­i­gi­ble for a Covid shot since June, on­ly 6.4% of kids un­der 2 years old have re­ceived at least one dose. Among kids 5 to 11, who have been el­i­gi­ble since last Oc­to­ber, 39.2% have re­ceived at least one shot.

Most kids who were un­vac­ci­nat­ed back in Ju­ly had a par­ent who was open to vac­ci­na­tion (59.3%), ac­cord­ing to a CDC study con­duct­ed over the sum­mer. How­ev­er, a sig­nif­i­cant por­tion of un­vac­ci­nat­ed chil­dren (37.2%) had a vac­cine-hes­i­tant par­ent.

CDC di­rec­tor Rochelle Walen­sky said in Sep­tem­ber that a sol­id up­take of the bi­va­lent boost­ers could save thou­sands of lives and bil­lions of dol­lars, and the White House has en­cour­aged peo­ple to get vac­ci­nat­ed along with their an­nu­al flu shot.

“As this virus has changed, and im­mu­ni­ty from pre­vi­ous Covid-19 vac­ci­na­tion wanes, the more peo­ple who keep up to date on Covid-19 vac­ci­na­tions, the more ben­e­fit there will be for in­di­vid­u­als, fam­i­lies and pub­lic health by help­ing pre­vent se­vere ill­ness­es, hos­pi­tal­iza­tions, and deaths,” FDA Com­mis­sion­er Robert Califf said in a news re­lease this morn­ing.

Bi­va­lent boost­ers are now avail­able for chil­dren 6 months to 5 years old who com­plet­ed their pri­ma­ry se­ries of the Mod­er­na vac­cine at least two months ago, and chil­dren 6 months to 4 years old who haven’t yet com­plet­ed their three-dose pri­ma­ry se­ries of the Pfiz­er-BioN­Tech vac­cine. The boost­er will serve as the third 3-µg dose in that case, fol­low­ing two dos­es of the orig­i­nal Pfiz­er-BioN­Tech vac­cine.

Kids be­tween 6 months and 4 years old who have al­ready re­ceived three dos­es of the Pfiz­er-BioN­Tech vac­cine are not yet el­i­gi­ble for a boost­er. The FDA said the “da­ta to sup­port giv­ing an up­dat­ed bi­va­lent boost­er dose for these chil­dren are ex­pect­ed in Jan­u­ary,” and it has promised to re­view the da­ta as quick­ly as pos­si­ble.

Pfiz­er said in a state­ment on Thurs­day that it’s ready to ship dos­es “im­me­di­ate­ly up­on rec­om­men­da­tion by CDC.”

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Troy Tazbaz, FDA's newly-named director of the Digital Health Center of Excellence (Oracle via YouTube)

Or­a­cle ex­ec­u­tive Troy Tazbaz named new FDA di­rec­tor of dig­i­tal health

The FDA has found a brand new director of the Digital Health Center of Excellence in Troy Tazbaz, a former senior vice president at Oracle.

According to Tazbaz’s LinkedIn, he took a five-month break after leaving an 11-year career at Oracle before joining the FDA in January. Stat News first reported the hire. Tazbaz also said on his LinkedIn that he biked all the way from Chesapeake Bay to the San Francisco Bay over 58 days during his career break.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Richard Gonzalez, AbbVie CEO (Chris Kleponis/picture-alliance/dpa/AP Images)

Up­dat­ed: $100B+ in sav­ings? Why the in­com­ing Hu­mi­ra biosim­i­lars will take time to catch on

The 20-year reign of AbbVie’s best-selling biologic of all time — the autoimmune disease biologic Humira (adalimumab) that has brought in upwards of $200 billion during its monopoly — is coming to an end tomorrow with the launch of Amgen’s biosimilar Amjevita.

The launch comes more than four years after Europe saw the exact same competition, leading to steep discounts in price, higher uptake, and big cost savings across the board.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.